July 25-27 2017

The Hyatt Regency, Boston, MA

Register by Friday, June 16 to save $400

Accelerate The Development & Commercialization Of Better Ocular Drugs

The growing disease burden and emergence of innovative new therapeutics means that the multi-billion dollar ophthalmic drug market is poised for near double digit compound growth over the next 5 years. There is enormous untapped potential for companies focusing on developing novel approaches to tackle age related macular degeneration, diabetic macular edema, glaucoma and other degenerative ocular conditions.

Focussing specifically on the challenges drug developers face in the development and delivery of clinically effective ocular drugs, the 2nd Annual Ophthalmic Drug Development Summit is your opportunity to fast-track your development efforts in this space.

Rather than covering early stage research or pipeline overviews, this meeting will unite leaders from Novartis, Genentech, Santen, Astellas and Spark Therapeutics to deliver granular, in-depth insights that will help you accelerate the progress of your ocular drug pipeline.

Find out more.

The multi-billion dollar ophthalmic drug market is poised for near double digit compound growth over the next 5 years.


"An excellent mix of topics from mid-stage to clinical testing, to market approval."

Head of Global Alliances & External Research, Santen

"This was one of the most productive meetings I have attended in many years"

CEO, Vestrum Health

Benefits Of Attending:

  • Seize the opportunities presented by gene therapy in ophthalmology
  • Improve compliance and enhance pharmacological effects
  • Successfully capitalize on novel targets and mechanisms of action
  • Navigate the regulatory landscape effectively